Longboard Pharmaceuticals Inc
NASDAQ:LBPH

Watchlist Manager
Longboard Pharmaceuticals Inc Logo
Longboard Pharmaceuticals Inc
NASDAQ:LBPH
Watchlist
Price: 59.98 USD Market Closed
Market Cap: 2.3B USD

Longboard Pharmaceuticals Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Longboard Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Longboard Pharmaceuticals Inc
NASDAQ:LBPH
Cash from Operating Activities
-$65.9m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$24.2B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$16.6B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
25%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$13.1B
CAGR 3-Years
-21%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$17.1B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
9%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$16.1B
CAGR 3-Years
26%
CAGR 5-Years
19%
CAGR 10-Years
17%
No Stocks Found

Longboard Pharmaceuticals Inc
Glance View

Market Cap
2.3B USD
Industry
Pharmaceuticals

Nestled in the bustling biotech landscape, Longboard Pharmaceuticals Inc. has carved its niche by steering its focus toward developing transformative therapies for neurological diseases. Born from the strategic insights honed within Arena Pharmaceuticals, Longboard carries forward an unwavering commitment to unraveling the complexities of neurobiology. At its core, the company's research is laser-focused on advancing a robust pipeline, notably targeting conditions with high unmet needs such as epilepsy and other neuropsychiatric disorders. The cornerstone of their approach lies in leveraging cutting-edge science to target specific neurological pathways, thus fostering innovative drug candidates that hold the potential to redefine treatment paradigms. The financial engine of Longboard turns primarily on its potential to bring successful therapies to market. Like many firms in the biotech sector, its journey from the lab bench to patient bedside is fraught with substantial R&D investments, clinical trial navigation, and regulatory hurdles. The promise of substantial returns hinges on achieving significant breakthroughs, securing FDA approval, and eventually commercializing their therapies. Additional revenue streams might emerge through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical entities, which can provide both immediate funding and shared resources to propel their products forward. Ultimately, Longboard’s financial health is intertwined with its scientific progress and regulatory milestones, painting a picture of a company deeply embedded in the rhythms of innovation and impact-driven healthcare solutions.

LBPH Intrinsic Value
Not Available

See Also

What is Longboard Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-65.9m USD

Based on the financial report for Sep 30, 2024, Longboard Pharmaceuticals Inc's Cash from Operating Activities amounts to -65.9m USD.

What is Longboard Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-48%

Over the last year, the Cash from Operating Activities growth was -33%. The average annual Cash from Operating Activities growth rates for Longboard Pharmaceuticals Inc have been -48% over the past three years .

Back to Top